Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (25784)	9/25/1998 5:11:00 PM
From: Alper H.YUKSEL	Respond to of 32384

Today, Jim Jubak of Microsoft Investor has come up with a shortlist of biotechs to hold for the long term, as he seperated biotechs from his picks a while ago; ICOS, ISIP, LGND, VRTX, and VICL (in alphabetical order) investor.msn.com Very brief info on LGND (and some important details like ONTAK missing too), but it fits his 4 criteria for buying a biotech : 1. Buy core-enabling technologies 2. Buy cheap companies 3. Buy products in the pipeline 4. Buy companies with a cash cushion 'Ligand Pharmaceuticals $9.66. Market capitalization: $354 million. Cash on hand: $52 million. Ligand has built up an expertise in making small-molecule drugs that regulate the intracellular receptors. The company's drugs bind with these receptors to tell the cell to block a signal. The company's technology shows promise in regulating the flow of estrogen -- crucial in treating osteoporosis -- and in treating cancer tumors. But partner Eli Lilly (LLY) is helping to fund research that will expand Ligand's approach to diabetes, cardiovascular disease, and metabolic disorders such as obesity. News for the remainder of 1998 and into 1999 is expected to include approval and launch of Panretin Gel for Kaposi's sarcoma, and filing for approval of Targretin in the treatment of cutaneous T-cell lymphoma. Analysts expect the company to break into the black in 1999. (Full disclosure: I own shares of Ligand.)' With the exception of VRTX, he owns share in all his picks. On a final note he states for ISIP and LGND :'Both stocks are now very attractively priced for the long-term investor.I continue to own shares of both companies in my personal portfolio and have added to my positions in both stocks on recent weakness.'